NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$83.16
-2.75 (-3.20%)
Close of Nov 06, 2026 · end-of-day data
CRVL 8-K filings in 2025
Every material Form 8-K CorVel filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CorVel reported results for the three months ended September 30, 2025, with revenue of $240 million, up from $224 million a year earlier, and diluted earnings per share of $0.54, up from $0.45. For the six months, revenue was $474 million and diluted EPS was $1.06, compared with $436 million and $0.87 a year earlier. The filing furnishes the November 4, 2025 press release and does not include guidance.
Q2 revenue of $240 million, up 7%; gross profit of $58.2 million, up 15%, at a 24% gross margin
Q2 diluted EPS of $0.54 versus $0.45 a year earlier; net income of $27.9 million
Six-month revenue of $474 million and diluted EPS of $1.06, versus $436 million and $0.87
Ended the quarter with $207 million in cash and no borrowings; repurchased $12.8 million of common stock
CorVel's chief financial officer, Brandon O'Brien, is transitioning out of the role effective September 10, 2025, and will stay on as a consultant to help with the handover. The board appointed Brian Nichols, a 15-year company veteran, as CFO effective immediately upon O'Brien's transition. The filing discloses a change in the company's top finance role but no financial results or outlook.
Brandon T. O'Brien, CFO, transitions out effective September 10, 2025, after 23 years with the company, and will provide transition support as a consultant
Brian Nichols, age 45, appointed CFO by the board on September 10, 2025, effective immediately upon O'Brien's transition
Nichols' annual base salary increased to $275,000, with eligibility for a discretionary bonus and stock option grants
CorVel reported results for the quarter ended June 30, 2025, with revenue of $235 million, up from $212 million a year earlier, and diluted earnings per share of $0.52, up from $0.42. The company also said it completed, in July, the acquisition of assets and key talent from a privately held technology firm to strengthen its CERIS group health division; the filing does not state the purchase price.
Revenue rose 11% to $235 million, versus $212 million in the June quarter of 2024.
Diluted EPS rose 24% to $0.52 from $0.42, adjusted for the three-for-one stock split paid December 24, 2024.
Gross profit rose 18% to $56.8 million, at a 24% gross margin, versus $48.2 million a year earlier.
Cash was $202 million with no borrowings at quarter end; the company repurchased $9.6 million of common stock during the quarter.
CorVel reported results for the three months and fiscal year ended March 31, 2025, with revenue and earnings per share both higher than a year earlier. For the quarter, revenue rose to $232 million and diluted EPS rose to $0.51 from $0.37, and the company repurchased $9.0 million of common stock. The results show growth in both sales and profit for shareholders.
Q4 revenue was $232 million, up 12% from $207 million a year earlier.
Q4 diluted EPS was $0.51, up 38% from $0.37; gross profit rose 34% to $58.0 million at a 25% gross margin.
Fiscal year revenue was $896 million, up from $795 million, and fiscal year diluted EPS was $1.83, up from $1.47.
The company ended the quarter with $171 million of cash and no borrowings, and repurchased $9.0 million of stock during the quarter.
CorVel reported results for the quarter ended December 31, 2024, with revenue of $228 million, up from $202 million a year earlier, and diluted earnings per share of $0.46, up from $0.33. Both headline measures improved, and the company ended the quarter with $163 million in cash and no borrowings. Per-share figures are adjusted for the three-for-one stock split paid December 24, 2024.
Quarterly revenue rose 13% to $228 million; nine-month revenue rose to $664 million from $588 million.
Quarterly gross profit rose 25% to $52.9 million, a 23.2% gross margin, versus $42.2 million a year earlier.
Nine-month diluted EPS was $1.32, compared with $1.09 in the prior-year period, adjusted for the stock split.
The company repurchased $9.6 million of common stock during the quarter and ended with $163 million in cash and no borrowings.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CorVel filing is on SEC EDGAR ↗. 8-K briefs of other companies →